Dose Insider / Glossary / Dual agonist

Dual agonistWhat it means and which GLP-1 drugs are one

Updated November 20, 2026 路 4 min read 路 MOUNJARO and ZEPBOUND labels, NEJM and Lancet trials 2023-2026

A dual agonist is a single molecule that activates two different hormone receptors. Among weight and diabetes medicines the term covers drugs that act on the GLP-1 receptor plus one more.

20.9%Tirzepatide, 72 weeks, weight lost, dual agonists
Weight lost, dual agonistsTop dose in each main trial, % of weightTirzepatide, 72 weeks20.9%Survodutide, 46 weeks14.9%Mazdutide, 48 weeks14.0%Weight lost, dual agonistsTop dose in each main trial, % of weightTirzepatide, 72 weeks20.9%Survodutide, 46 weeks14.9%Mazdutide, 48 weeks14.0%

Different trials, people and lengths; not a head-to-head comparison.

On this page

Tirzepatide, in Mounjaro and Zepbound, adds the GIP receptor. Survodutide and mazdutide, which have no U.S. label, add the glucagon receptor. A medicine like semaglutide, which acts on the GLP-1 receptor alone, is sometimes called a selective or single agonist by contrast.1,2,3,4

Why aim at two receptors

Each gut and pancreatic hormone has its own effects. GLP-1 raises insulin, lowers glucagon, slows the stomach and reduces food intake.5 GIP is the other incretin, and a 2025 review argues its receptor also acts in the brain and in fat tissue.6 Glucagon acts mainly on the liver, which is why survodutide was tested for liver fat.3 Combining two actions in one molecule is meant to add their benefits while keeping a single weekly injection.

The two families

MoleculeReceptorsStatus in the sources here
TirzepatideGIP and GLP-1U.S. label since 2022, as Mounjaro and Zepbound
SurvodutideGlucagon and GLP-1Phase 3 trials
MazdutideGLP-1 and glucagonPhase 3 trial in China
PemvidutideGLP-1 and glucagonPhase 2 trials

Labels and trial reports listed below.1,2,3,4,7

The evidence from tirzepatide

Tirzepatide is the dual agonist with the most data. A 2022 review describes it as the first dual GIP and GLP-1 receptor agonist approved for type 2 diabetes. Across five diabetes trials it lowered HbA1c by 1.24 to 2.58 points and weight by 5.4 to 11.7 kg.8 In the Zepbound weight trial, 15 mg lowered weight by 20.9% over 72 weeks.2 Against semaglutide directly, it lowered weight more in both SURPASS-2 and SURMOUNT-5: 20.2% against 13.7% in the obesity trial.1,9 Those comparisons show the dual agonist doing better than semaglutide at the doses tested; they cannot show how much of the gap comes from the GIP receptor alone.

The glucagon pairs

Survodutide lowered weight by up to 14.9% over 46 weeks in a phase 2 trial, and in a 2026 liver trial 84.2% of people saw liver fat fall by at least 30%.3,10 Mazdutide lowered weight by 14.01% on 6 mg over 48 weeks in Chinese adults.4 Pemvidutide, a third drug of this kind, was tested mainly for a scarring form of fatty liver disease.7

Close relatives that are not dual agonists

Two neighbors are easy to confuse with this group. Retatrutide adds a third receptor, glucagon, to tirzepatide's two, so it is called a triple agonist; in its phase 3 trial weight fell by 25.0% on 12 mg over 80 weeks.11 MariTide, from Amgen, also acts on the GLP-1 and GIP receptors, but it activates the first and blocks the second, so it is an agonist and an antagonist at once.12

Reading dual-agonist results

Three cautions apply when comparing numbers. Weight loss is smaller in people with type 2 diabetes: 14.7% on Zepbound 15 mg against 20.9% without diabetes in its label trials.2 Trials differ in how they count people who stop the drug; in the survodutide phase 2 trial only 60.4% completed the 46 weeks.3 And the people enrolled differ: GLORY-1 enrolled Chinese adults weighing 87.2 kg on average, in whom weight on placebo did not fall at all.4

Side effects

Every dual agonist in these trials shared the main side effects of the GLP-1 class: nausea, vomiting, diarrhea and constipation, most often during the dose climb.2,3,4 A second receptor has not removed them. Our page on nausea on a GLP-1 covers what helps.

Sources

  1. MOUNJARO (tirzepatide) prescribing information, NDA 215866/S-052, revised April 2026. U.S. Food and Drug Administration; sections 12.1 and 14. accessdata.fda.gov
  2. ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; sections 6.1, 12.1 and 14. accessdata.fda.gov
  3. le Roux CW, Steen O, Lucas KJ, et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol 2024;12:162-173. doi:10.1016/S2213-8587(23)00356-X
  4. Ji L, Jiang H, Bi Y, et al. Once-weekly mazdutide in Chinese adults with obesity or overweight (GLORY-1). N Engl J Med 2025;392:2215-2225. doi:10.1056/NEJMoa2411528
  5. Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab 2018;27:740-756. doi:10.1016/j.cmet.2018.03.001
  6. Samms RJ, Sloop KW. A contemporary rationale for agonism of the GIP receptor in the treatment of obesity. Diabetes 2025;74:1326-1333. Both authors are employees of Eli Lilly and Company. doi:10.2337/dbi24-0026
  7. Noureddin M, Harrison SA, Loomba R, et al. Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a phase 2b study. Lancet 2025;406:2644-2655. Funded by Altimmune. doi:10.1016/S0140-6736(25)02114-2
  8. Nauck MA, D'Alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regarding glycaemic control and body weight reduction. Cardiovasc Diabetol 2022;21:169. doi:10.1186/s12933-022-01604-7
  9. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med 2025;393:26-36. nejm.org
  10. Kaplan LM, Startseva E, le Roux CW, et al. Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD. Nat Med 2026;32:2948-2958. doi:10.1038/s41591-026-04479-3
  11. Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a triple hormone receptor agonist, for treatment of obesity (TRIUMPH-1). N Engl J Med 2026;395:1781-1793. doi:10.1056/NEJMoa2604169
  12. Jastreboff AM, Ryan DH, Bays HE, et al. Once-monthly maridebart cafraglutide for the treatment of obesity: a phase 2 trial. N Engl J Med 2025;393:843-857. doi:10.1056/NEJMoa2504214

Related analyses

Log any GLP-1 medicine you take and see your doses, weight and symptoms together.

Open Dose Insider